研究人員>黃明熙 (Ming-Hsi Huang)

感染症與疫苗研究所
連絡電話:+886-37-206166 # 37742 (O) or 37749 (Lab)
傳真電話:+886-37-583009
E-mail:huangminghsi@nhri.org.tw
 

學歷

2001/10 – 2004/12     Ph.D., Faculty of Pharmacy, University of Montpellier 1, Montpellier, France
1997/09 – 1999/07     M.S., Institute of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan
1993/09 – 1997/06     B.S., Department of Chemical Engineering, National Cheng-Kung University, Tainan, Taiwan

經歷

2015/08 – present Certificate Associate Professor, Minister of Education, Taiwan
2014/04 – present Associate Investigator, NIIDV, NHRI, Miaoli, Taiwan
2009/08 – 2014/03 Assistant Investigator, NIIDV, NHRI, Miaoli, Taiwan
2005/07 – 2009/08  Postdoctoral Fellow, Vaccine R&D Center, NHRI, Miaoli, Taiwan
1999/09 – 2001/05  Military service
   

Honors & Awards

2019 Young Scientist Award in National Health Research Institutes, Taiwan
2018 Futuristic Breakthrough Technology Award in Ministry of Science and Technology, Taiwan
1997 Research Creativity Award for undergraduate in National Science Council, Taiwan

 

Research Interests

BEL Image Video: [Polysorbasome]

Dr. Huang’s major research interest at NIIDV has been focused on the development of novel delivery vehicles for generating vaccine-induced long-term immunity as well as immunoregulatory agents for manipulating effective/harmful immune responses. At the outset, the studies were involved in the engineering of amphiphilic bioresorbable polymers in the pursuit of innovative vaccine design for a single-dose multivalent vaccine against emerging infectious diseases, in particular influenza-associated illness and hand-foot-mouth disease. This platform also offers several advances including antigen sparing, mucosal delivery and cancer immunotherapy. Currently, he is working on how emulsion adjuvants interacting with immune cells and mechanism elucidation of manufacturing process and each component linking with vaccination routes and vaccine immunogenicity.

Research Activities & Accomplishment

In order to establish self-manufacturing capability for preparedness to any pandemic outbreak, National Institute of Infectious Diseases and Vaccinology (NIIDV) is currently developing cutting-edge technologies to rapidly produce sufficient quantities of vaccine supplies for massive vaccination. Among these, adjuvantation is a potential strategy to diminish antigen consumption by enhancing antigen-specific immunogenicity, i.e. antigen-sparing effect. However, traditional aluminum-based adjuvants (Alum), which are highly heterogeneous and difficult to manufacture in a consistent and reproducible manner, are obstacles in pandemic vaccine preparedness. Regarding this, it will be important to investigate the feasibility of enhancing vaccine immunogenicity with non-Alum-based adjuvants in vaccine formulations.

 

Immunobioengineering Laboratory (iBEL) of NIIDV is tasked with integrating immunobiology and engineering to facilitate the development of vaccine formulation and delivery for the induction of broadened and appropriate immune responses. Under the funding resources from NHRI and MOST, our research group has set up the platform technologies for vaccine formulation and delivery, including polymer synthesis, vaccine formulation, and immunological evaluation, as well as safety aspects and distribution of antigen and adjuvant in vivo. This platform offers several important advantages including antigen sparing, single injection, mucosal delivery, and cancer therapy.

 

Research frameworks. At the outset, we study on the engineering of amphiphilic bioresorbable polymers as a promising strategy for the delivery of vaccine antigens and/or immunostimulatory molecules; in parallel, we design and synthesize small antimicrobial peptide analogues. We also feature a mouse model for studying and understanding the properties of the candidate adjuvants interacting with immune cells as well as the roles in vaccine immunogenicity. In vivo distribution is investigated in mice to elucidate the targeting delivery of antigen-loaded systems. The histological examination of the tissue or organ integrities as well as the serum biochemistry test to study whether the novel compounds can turn on harmful reactions after injection in mice. Based on this platform, our research group has designed different vaccine formulations based on squalene emulsions as adjuvants for NIIDV candidate vaccines and investigated respective mode of action linking the physicochemical properties and the adjuvant activity. These experiences allowed us to foster the development of biotech companies in vaccine manufacturing and vaccine-related biotechnology.

Engineering amphiphilic bioresorbable polymers in the pursuit of innovative vaccine design. It has been well documented that the emulsions made by conventional emulsifiers such as sorbitan esters (Span®) or their ethoxylates (Tween®) may cause serious side effects, including severe non-immunological anaphylactoid reactions. Therefore, there is an unmet medical need to increase the number of well-defined emulsifiers in the preparation of emulsion-based vaccine adjuvants towards enhancing the vaccine efficacy without alternating the safety aspects. Toward this, a colloidal vesicle consisting of two immiscible liquids, metabolizable oil and aqueous solution, was stabilized by amphiphilic bioresorbable polymers consisting of hydrophilic groups and lipophilic groups. The hydrophilic group was made of poly(ethylene glycol) (PEG) or sorbitan; on the other hand, the lipophilic group comprised polyesters derived from lactyl (LA) and caproyl (CL) motifs, which have been widely regarded as degradable polyesters. These amphiphilic bioresorbable polymers act as surface-active agents to stabilize the oil/water interfaces and give rise to oil-shelled polysorbasomes (polymeric absorbable vesicles) during preparation and storage. The multiple phase character prolongs the retention of bioactive molecules. Following vaccination, the degradability intrinsic to bioresorbable polymers complies the vehicles’ being destroyed and further being absorbed in vivo. These features provide new insights into the field of sustained delivery based on bioresorbable amphiphilic engineering.

 

The merits of this invention are as follows:

  1. 安全Safe: All excipients used here showed main chain cleavage into small molecules and further absorbance in vivo, thereby conceptually conserving the vaccine safety.
  2. 柔軟Soft: Liquid–liquid colloidal vesicles are deformable and easily injected by a syringe with a small gauge needle, thereby potentially diminishing local reactions at the injection site. This feature encourages the use of such vesicles for massive vaccination.
  3. 細緻Small: Homogeneous colloidal particles can be controlled by passing them through an extruder membrane, and their size can therefore be controlled from 1,000 to 100 nm, thus facilitating the induction of appropriate immunity.
  4. 靈巧Smart: Oil-shelled capsules are useful for encapsulating and protecting designed bioactive molecules; the loss of the lipophilic moiety of amphiphiles directly affected the stability of the colloid after vaccination.
  5. 簡便Simple: The raw materials for colloids elaboration are commercially available and are largely used for vaccine/drug delivery; in addition, no complicating processes or supplemental equipment is required when performing the vaccine formulation, thus effectively reducing the cost.
  6. 善誘Stimulatory: Colloidal particles are immunogenic and facilitate the activation of immune cells, such that antigen-specific antibodies and cell-mediated immunity could be manipulated after the antigen being formulated with colloids.

 

Comments are closed.